...
首页> 外文期刊>Pediatric nephrology: journal of the International Pediatric Nephrology Association >MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.
【24h】

MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.

机译:儿童MDR-1基因多态性与类固醇反应性肾病综合征的临床过程。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The study was aimed at investigating the association between MDR-1 genetic polymorphisms [C1236T, G2677T(A), C3435T] and parameters describing the clinical course and treatment response of childhood steroid-responsive nephrotic syndrome (SRNS). Three MDR-1 genetic markers were analyzed in 108 children diagnosed with SRNS and in 135 healthy controls with neither allergic nor renal disease. All subjects were genotyped by PCR-restriction fragment length polymorphism (RFLP) analysis, and an EM algorithm-based analysis was utilized to estimate haplotype frequencies. As expected, there was no difference in genotypic and allelic distribution between and among SRNS patients and healthy children. However, all individual polymorphisms were strongly associated with time to response to initial prednisone therapy. The frequencies of the mutated alleles were higher in late responders (time to remission: >7 days) to oral prednisone (0.53, 0.52,0.66) than in early responders (time to remission: <7 days; 0.24, 0.19, 0.32), with all p values <0.001 for positions 1236, 2677 and 3435, respectively). Odds ratios (ORs) reflecting the strength of the associations were as follows: 6.79 (95% CI:1.96- 23.54) for 1236 T/T, 13.7 (95% CI:2.78-67) for 2677 T/T and 9.92 (95% CI: 3.01-32.71) for 3435 T/T as compared to the respective-wild type homozygotes. The TTT haplotype was similarly found to be significantly associated with late oral steroid response (0.49 vs. 0.19, p=0.0003). Variants 1236T, 2677TA and 3435T identify patients that respond slower to oral prednisone. Although the functional properties of the substitutions investigated here are still to be determined, our findings may be a small step toward the optimization of immunosuppressive therapy in SRNS children.
机译:该研究旨在调查MDR-1基因多态性[C1236T,G2677T(A),C3435T]与描述儿童类固醇反应性肾病综合征(SRNS)的临床过程和治疗反应的参数之间的关联。在108名被诊断患有SRNS的儿童和135名既没有变态反应也没有肾脏疾病的健康对照中分析了三种MDR-1遗传标记。通过PCR-限制性片段长度多态性(RFLP)分析对所有受试者进行基因分型,并且基于EM算法的分析用于估计单倍型频率。不出所料,SRNS患者与健康儿童之间的基因型和等位基因分布没有差异。然而,所有个体多态性都与对初始泼尼松治疗的反应时间密切相关。口服泼尼松的晚期应答者(缓解时间:> 7天)的突变等位基因频率(0.53、0.52、0.66)比早期应答者(缓解时间<7天; 0.24、0.19、0.32)更高。位置1236、2677和3435的所有p值均<0.001)。反映关联强度的几率(OR)如下:1236 T / T为6.79(95%CI:1.96- 23.54),2677 T / T为13.7(95%CI:2.78-67)和9.92(95)与相应的野生型纯合子相比,对于3435 T / T,%CI:3.01-32.71)。类似地,发现TTT单倍型与晚期口服类固醇反应显着相关(0.49 vs. 0.19,p = 0.0003)。变体1236T,2677TA和3435T识别出对口服泼尼松反应较慢的患者。尽管此处研究的取代基的功能特性尚待确定,但我们的发现可能是优化SRNS儿童免疫抑制疗法的一小步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号